FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330024675> ?p ?o ?g. }

• W2330024675 endingPage "27266" @default.
• W2330024675 startingPage "27255" @default.
• W2330024675 abstract "// Tomasz Czerw 1 , Myriam Labopin 2,3,4 , Christoph Schmid 5 , Jan J. Cornelissen 6 , Patrice Chevallier 7 , Didier Blaise 8 , Jürgen Kuball 9 , Stephane Vigouroux 10 , Frédéric Garban 11 , Bruno Lioure 12 , Nathalie Fegueux 13 , Laurence Clement 14 , Anna Sandstedt 15 , Johan Maertens 16 , Gaëlle Guillerm 17 , Dominique Bordessoule 18 , Mohamad Mohty 2,3,4,* and Arnon Nagler 19,2,* 1 Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Gliwice, Poland 2 Clinical Hematology and Cellular Therapy Department, The Acute Leukemia Working Party of the EBMT office, Hopital Saint-Antoine APHP Paris, France 3 INSERM UMRs 938, Paris, France 4 Université Pierre et Marie Curie (UPMC, Paris VI), Paris, France 5 Klinikum Augsburg, University of Munich, Munich, Germany 6 Department of Hematology, Erasmus University medical center Cancer Institute, Rotterdam, The Netherlands 7 CHU Nantes, Dept. D`Hematologie, Nantes, France 8 Unité de transplantation et de thérapie cellulaire, Institut Paoli Calmettes, Marseille, France 9 University Medical Centre, Dept. of Haematology, Utrecht, The Netherlands 10 CHU Bordeaux, Hôpital Haut-leveque, Pessac, France 11 Hopital A. Michallon, Hématologie Clinique, Pole Cancérologie, Grenoble, France 12 Nouvel Hopital Civil, Strasbourg, France 13 CHU Lapeyronie, Département d`Hématologie Clinique, Montpellier, France 14 Hôpital de Brabois, Centre Hospitalier Universitaire (CHU) de Nancy, Vandoeuvres les Nancy, France 15 University Hospital, Dept. of Hematology, Linköping, Sweden 16 University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium 17 CHU Morvan, Brest, France 18 CHRU Limoges, Service d`Hématologie Clinique, Limoges, France 19 Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel * These authors have contributed equally to this work Correspondence to: Tomasz Czerw, email: // Keywords : allogenic transplantation, stem cell transplantation, acute myeloid leukemia (AML), reduced-intensity conditioning, cell dose Received : March 17, 2016 Accepted : March 23, 2016 Published : March 29, 2016 Abstract Inconsistent results have been reported regarding the influence of graft composition on the incidence of graft versus host disease (GVHD), disease control and survival after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell transplantation (allo-PBSCT). These discrepancies may be at least in part explained by the differences in disease categories, disease status at transplant, donor type and conditioning. The current retrospective EBMT registry study aimed to analyze the impact of CD3+ and CD34+ cells dose on the outcome of RIC allo-PBSCT in patients with acute myelogenous leukemia (AML) in first complete remission, allografted from HLA-matched unrelated donors (10 of 10 match). We included 203 adults. In univariate analysis, patients transplanted with the highest CD3+ and CD34+ doses (above the third quartile cut-off point values, >347 x 10^6/kg and >8.25 x 10^6 /kg, respectively) had an increased incidence of grade III-IV acute (a) GVHD (20% vs. 6%, P = .003 and 18% vs. 7%, P = .02, respectively). There was no association between cellular composition of grafts and transplant-related mortality, AML relapse, incidence of chronic GVHD and survival. Neither engraftment itself nor the kinetics of engraftment were affected by the cell dose. In multivariate analysis, CD3+ and CD34+ doses were the only adverse predicting factors for grade III-IV aGVHD (HR = 3.6; 95%CI: 1.45-9.96, P = .006 and 2.65 (1.07-6.57), P = .04, respectively). These results suggest that careful assessing the CD3+ and CD34+ graft content and tailoring the cell dose infused may help in reducing severe acute GVHD risk without negative impact on the other transplantation outcomes." @default.
• W2330024675 created "2016-06-24" @default.
• W2330024675 creator A5006796325 @default.
• W2330024675 creator A5015832963 @default.
• W2330024675 creator A5019072713 @default.
• W2330024675 creator A5020996390 @default.
• W2330024675 creator A5022161221 @default.
• W2330024675 creator A5025108931 @default.
• W2330024675 creator A5036207495 @default.
• W2330024675 creator A5040417184 @default.
• W2330024675 creator A5046927330 @default.
• W2330024675 creator A5049426974 @default.
• W2330024675 creator A5053031492 @default.
• W2330024675 creator A5058925624 @default.
• W2330024675 creator A5066560929 @default.
• W2330024675 creator A5069084023 @default.
• W2330024675 creator A5076453784 @default.
• W2330024675 creator A5085266520 @default.
• W2330024675 creator A5086668079 @default.
• W2330024675 creator A5090291825 @default.
• W2330024675 date "2016-03-29" @default.
• W2330024675 modified "2023-10-16" @default.
• W2330024675 title "High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia — an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation" @default.
• W2330024675 cites W1219495269 @default.
• W2330024675 cites W1491993932 @default.
• W2330024675 cites W1530764705 @default.
• W2330024675 cites W1550454468 @default.
• W2330024675 cites W1620751085 @default.
• W2330024675 cites W1918510565 @default.
• W2330024675 cites W1964528954 @default.
• W2330024675 cites W1973617793 @default.
• W2330024675 cites W1976780386 @default.
• W2330024675 cites W1982439911 @default.
• W2330024675 cites W1994075039 @default.
• W2330024675 cites W1997427581 @default.
• W2330024675 cites W2004644657 @default.
• W2330024675 cites W2010409138 @default.
• W2330024675 cites W2017886426 @default.
• W2330024675 cites W2027090443 @default.
• W2330024675 cites W2037886497 @default.
• W2330024675 cites W2038981426 @default.
• W2330024675 cites W2069968835 @default.
• W2330024675 cites W2076267122 @default.
• W2330024675 cites W2090116626 @default.
• W2330024675 cites W2099413806 @default.
• W2330024675 cites W2099538280 @default.
• W2330024675 cites W2106371762 @default.
• W2330024675 cites W2106781384 @default.
• W2330024675 cites W2138198874 @default.
• W2330024675 cites W2144411376 @default.
• W2330024675 cites W2152197116 @default.
• W2330024675 cites W2167765664 @default.
• W2330024675 cites W2236173579 @default.
• W2330024675 cites W2339881237 @default.
• W2330024675 cites W4293241248 @default.
• W2330024675 doi "https://doi.org/10.18632/oncotarget.8463" @default.
• W2330024675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5053647" @default.
• W2330024675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27036034" @default.
• W2330024675 hasPublicationYear "2016" @default.
• W2330024675 type Work @default.
• W2330024675 sameAs 2330024675 @default.
• W2330024675 citedByCount "50" @default.
• W2330024675 countsByYear W23300246752016 @default.
• W2330024675 countsByYear W23300246752017 @default.
• W2330024675 countsByYear W23300246752018 @default.
• W2330024675 countsByYear W23300246752019 @default.
• W2330024675 countsByYear W23300246752020 @default.
• W2330024675 countsByYear W23300246752021 @default.
• W2330024675 countsByYear W23300246752022 @default.
• W2330024675 countsByYear W23300246752023 @default.
• W2330024675 crossrefType "journal-article" @default.
• W2330024675 hasAuthorship W2330024675A5006796325 @default.
• W2330024675 hasAuthorship W2330024675A5015832963 @default.
• W2330024675 hasAuthorship W2330024675A5019072713 @default.
• W2330024675 hasAuthorship W2330024675A5020996390 @default.
• W2330024675 hasAuthorship W2330024675A5022161221 @default.
• W2330024675 hasAuthorship W2330024675A5025108931 @default.
• W2330024675 hasAuthorship W2330024675A5036207495 @default.
• W2330024675 hasAuthorship W2330024675A5040417184 @default.
• W2330024675 hasAuthorship W2330024675A5046927330 @default.
• W2330024675 hasAuthorship W2330024675A5049426974 @default.
• W2330024675 hasAuthorship W2330024675A5053031492 @default.
• W2330024675 hasAuthorship W2330024675A5058925624 @default.
• W2330024675 hasAuthorship W2330024675A5066560929 @default.
• W2330024675 hasAuthorship W2330024675A5069084023 @default.
• W2330024675 hasAuthorship W2330024675A5076453784 @default.
• W2330024675 hasAuthorship W2330024675A5085266520 @default.
• W2330024675 hasAuthorship W2330024675A5086668079 @default.
• W2330024675 hasAuthorship W2330024675A5090291825 @default.
• W2330024675 hasBestOaLocation W23300246751 @default.
• W2330024675 hasConcept C126322002 @default.
• W2330024675 hasConcept C194409129 @default.
• W2330024675 hasConcept C2911091166 @default.
• W2330024675 hasConcept C71924100 @default.
• W2330024675 hasConceptScore W2330024675C126322002 @default.
• W2330024675 hasConceptScore W2330024675C194409129 @default.
• W2330024675 hasConceptScore W2330024675C2911091166 @default.
• W2330024675 hasConceptScore W2330024675C71924100 @default.

• next